The NCI BRB Program Staff provide oversight of the Biopharmaceutical Development Program (BDP) at the National Cancer Institute Frederick campus (NCI-Frederick). The BDP produces a variety of biopharmaceuticals under current Good Manufacturing Practices (cGMP) for Phase I/II human clinical trials or advanced preclinical animal testing. The BDP is operated under contract by Leidos Biomedical Research, Inc., which provides operations and technical support to the FCRDC.